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Jiang et al. report that immature human
astroglia derived from induced
pluripotent stem cells (hiPSC-Astros)
promote oligodendrocyte lineage
progression, in part by upregulating and
increasing the secretion of TMIP-1. In
animal models of neonatal brain injury,
mimicking cerebral palsy in humans, they
also demonstrate that transplanted
hiPSC-Astros or their conditioned
medium promote myelinogenesis as well
as behavioral outcome. The findings
provide insights into astroglial regulation
of oligodendrogenesis and have
important implications for astroglia-
based cell therapy.
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Astrocytes, once considered passive support cells,
are increasingly appreciated as dynamic regulators
of neuronal development and function, in part via
secreted factors. The extent to which they similarly
regulate oligodendrocytes or proliferation and differ-
entiation of oligodendrocyte progenitor cells (OPCs)
is less understood. Here, we generated astrocytes
from human pluripotent stem cells (hiPSC-Astros)
and demonstrated that immature astrocytes, as
opposed to mature ones, promote oligodendrogene-
sis in vitro. In the PVL mouse model of neonatal
hypoxic/ischemic encephalopathy, associated with
cerebral palsy in humans, transplanted immature
hiPSC-Astros promoted myelinogenesis and behav-
ioral outcome. We further identified TIMP-1 as a
selectively upregulated component secreted from
immature hiPSC-Astros. Accordingly, in the rat PVL
model, intranasal administration of conditioned
medium from immature hiPSC-Astros promoted
oligodendrocyte maturation in a TIMP-1-dependent
manner. Our findings suggest stage-specific devel-
opmental interactions between astroglia and oligo-
dendroglia and have important therapeutic implica-
tions for promoting myelinogenesis.INTRODUCTION
Astrocytes play important roles in organizing and maintaining
brain structure and function (Barres, 2008). Astrocytes go
through prenatal and protracted postnatal maturation during
development and can undergo a spectrum of functional changes
associated with development (Molofsky et al., 2012; Pekny and
Pekna, 2014), serving stage-specific roles in assisting neuronal
development, such as synapse stabilization and elimination
(Chung et al., 2013; Molofsky et al., 2012). However, it is unclear
how astrocytes, at specific immature and mature stages, mayCe
This is an open access article unddifferently regulate the development of oligodendrocytes,
myelin-producing cells in the CNS.
Human pluripotent stem cells (hPSCs), including human em-
bryonic stem cells (hESCs) and induced pluripotent stem
cells (iPSCs), have been efficiently differentiated to astrocytes
(Emdad et al., 2012; Jiang et al., 2013b; Krencik et al., 2011; Roy-
bon et al., 2013; Shaltouki et al., 2013). The progenies differenti-
ated from hPSCs are reflective of very early human development
(<6 weeks) (Patterson et al., 2012). Particularly, hPSC-derived
astrocytes differentiated by using chemically defined, xeno-
free protocols can be maintained at an immature stage in culture
(Chen et al., 2014a; Emdad et al., 2012; Jiang et al., 2013b; Kren-
cik et al., 2011; Shaltouki et al., 2013). Moreover, hPSC-derived
immature astrocytes can be further differentiated to astrocytes
with defined mature phenotypes (Krencik et al., 2011; Roybon
et al., 2013). Thus, astroglia derived from hPSCs provide an un-
precedented opportunity to investigate the interaction between
oligodendroglia and human astrocytes that are at defined imma-
ture and mature stages.
Astrocytes are implicated in influencing myelination in myelin
loss disorders. Prior studies demonstrate that oligodendrocytes
preferentially remyelinate axons in areas containing astrocytes
(Franklin et al., 1991; Talbott et al., 2005). However, astroglia-
based therapy for myelin loss disorders is less studied (Chen
et al., 2015) because most of the disorders are associated with
profound astrocyte activation and formation of glial scars (Pekny
and Pekna, 2014). Scarring astrocytes are regarded as a barrier
to regeneration, partly because of the secretion of factors that
halt survival and differentiation of oligodendroglia progenitor
cells (OPCs) (Back et al., 2005; Nash et al., 2011). Recent studies
also suggest that, in the acute phase of injuries, astrogliosis is a
defensive reaction. Reactive astrocytes recapitulate numerous
processes involved in the early development of immature astro-
glia and exhibit positive effects in the acute phase of injuries
(Pekny and Pekna, 2014), but reactivated processes often go
awry later, turning on the detrimental effects of the astrocytes
on regeneration (Gallo and Deneen, 2014). Recent studies (Jiang
et al., 2013b; Noble et al., 2011) demonstrate that transplanted
immature astrocytes do not become reactive after CNS injury.
Immature but not mature astrocytes are neuroprotective and
suppress the activation of endogenous astrocytes and glialll Reports 15, 1303–1315, May 10, 2016 ª 2016 The Authors 1303
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scar formation (Chen et al., 2015). Thus, there is a strong ratio-
nale to examine whether transplantation of hPSC-derived
astrocytes at a defined immature stage could regulate the differ-
entiation of endogenous OPCs and promote myelinogenesis.
Perinatally acquired white matter injury, induced by perinatal
hypoxia-ischemia and referred to as periventricular leukomala-
cia (PVL), is the most common cause of brain injury in premature
infants. PVL is the leading cause of cerebral palsy and long-term
neurological morbidity (Deng, 2010). Currently no effective treat-
ment exists. One of themajor causes of whitematter injury is that
pre-myelinating oligodendrocytes are particularly vulnerable in
PVL (Haynes et al., 2003). The decrease in pre-myelinating oligo-
dendrocytes leads to an upstream increase in OPCs, but these
OPCs are arrested at the progenitor stage and fail to efficiently
differentiate into myelin-producing oligodendrocytes (Fancy
et al., 2011; Jablonska et al., 2012; Reid et al., 2012; Segovia
et al., 2008). Here we report that immature hiPSC-derived astro-
cytes (hiPSC-Astros), but not mature hiPSC-Astros and mature
astrocytes isolated from the human brain, strongly promote the
proliferation of OPCs and differentiation of OPCs to oligodendro-
cytes. Moreover, immature hiPSC-Astros promote myelination
and recovery of behavioral performance in animal models of
PVL injury. Mechanistically, we show that immature hiPSC-
Astros regulate OPC differentiation via secreted molecules,
including tissue inhibitor of metalloproteinase 1 (TIMP-1), both
in vitro and in vivo.
RESULTS
Generation of Immature and Mature hiPSC-Astros
By using our established protocol (Jiang et al., 2013b), we
derived astroglia from two hiPSC lines generated fromhealthy in-
dividuals (Chen et al., 2014a; Figures S1A and S1B). These
hiPSC-Astros expressed the astroglial markers glial fibrillary
acidic protein (GFAP) and S100b (Figure S1C). We compared
the regional identities of the hiPSC-Astros with human brain-
derived astrocytes (hBrain-Astros) isolated from the cerebral
cortex of the human brain. Similar to hiPSC-Astros, hBrain-
Astros expressed the astroglial markers GFAP and S100b (Fig-
ure 1A). We found that the hBrain-Astros mainly expressed the
mid/forebrain marker OTX2 (Figures 1B and 1G) but not the hind-
brain/spinal cord-specific marker HOXB4 (Figures 1C and 1G).
There were nearly no hBrain-Astros expressing the ventral
marker NKX2.1 (<0.1%; Figures 1D and 1G). Similarly, the vast
majority of hiPSC-Astros also showed a mid/forebrain identity,
as indicated by expressing OTX2 (Figures 1B and 1G), but not
HOXB4 (<0.1%; Figures 1C and 1G). A small percentage of
hiPSC-Astros weakly expressed NKX2.1 (Figures 1C and 1G).
Nearly all hiPSC-Astros also expressed human CD44 (hCD44)
and vimentin (Figure S1D), suggesting that these hiPSC-Astros
were immature (Liu et al., 2004; Dahl et al., 1981; Jiang et al.,
2013b). We then induced immature hiPSC-Astros to become
mature astrocytes by treatment with fibroblast growth factor 1
(FGF1), leukemia inhibitory factor (LIF), and ciliary neurotrophic
factor (CNTF) (Krencik et al., 2011; Roybon et al., 2013). After
30- to 50-day treatment, we first examined the expression of
an astroglial maturation marker, nuclear factor 1A (NF1A) (De-
neen et al., 2006; Roybon et al., 2013), to verify the mature phe-1304 Cell Reports 15, 1303–1315, May 10, 2016notypes of these human astrocytes. The expression of NF1Awas
abundant in immature hiPSC-Astros but markedly reduced in
hBrain-Astros andmature hiPSC-Astros (Figure 1E). Quantitative
PCR results showed that immature hiPSC-Astros had a signifi-
cantly higher (3-fold) expression level of NF1A than hBrain-
Astros and mature hiPSC-Astros (Figure 1H). We further
examined the expression of hCD44 and vimentin in these human
astrocytes. Nearly all hiPSC-Astros, hBrain-Astros, and mature
hiPSC-Astros were positive for hCD44 and vimentin staining
(Figure 1F). However, qPCR results indicated a significantly
higher expression level of hCD44 in immature hiPSC-Astros
compared with hBrain-Astros (1.7-fold) and mature hiPSC-
Astros (2.6-fold) (Figure 1H). Moreover, qPCR results also
showed that immature hiPSC-Astros expressed the highest level
of vimentin, which was 2.2- and 5.3-fold higher than that in
hBrain-Astros and mature hiPSC-Astros, respectively (Fig-
ure 1H). The expression levels of hCD44 and vimentin were
higher in hBrain-Astros than in mature hiPSC-Astros (Figure 1H).
We further observed that, in human brain tissues derived from
normal patients at an age of less than 6 months, human imma-
ture astrocytes labeled in situ by GFAP or S100b also expressed
hCD44 and vimentin (Figures S1E and S1F).
We next quantified the expression of mRNAs encoding the
astrocyte-specific glutamate transporters excitatory amino acid
transporter 1 and 2 (EAAT1 and 2) in all astroglial preparations.
Consistent with a previous study (Roybon et al., 2013), we found
that EAAT1 was expressed at a higher level in mature hiPSC-
Astros (1.9-fold) and hBrain-Astros (2.3-fold) than in immature
hiPSC-Astros (Figure 1I), whereas the EAAT2 level was not signif-
icantly different. The hBrain-Astros expressed EAAT1 and 2 at
levels similar to mature hiPSC-Astros. In agreement with the
expression of glutamate transporters, hBrain-Astros and mature
hiPSC-Astros had a 1.6-fold increase in sodium-dependent
glutamate transport activity compared with immature hiPSC-
Astros (Figure 1J). In addition, it is generally accepted that
mature astrocytes are not proliferative. We also observed a
significantly lower proliferation rate of mature hiPSC-Astros
and hBrain-Astros than that of immature hiPSC-Astros (Fig-
ure 1K). Together, these data demonstrate that the hiPSC-Astros
in this study represent human astrocytes with immature pheno-
types, whereas hBrain-Astros and hiPSC-Astros treated with
FGF1 represent human astrocytes with mature phenotypes.
Immature hiPSC-Astros Promote the Proliferation
of OPCs
To develop an astroglia-based cell therapy for myelin loss disor-
ders, we first investigated how astroglia differentiated from
hiPSCs interact with oligodendroglia, particularly in the presence
of neurons. To this end, we fed a primary mixed neuron/glia cul-
ture at 7 days in vitro (DIV) with astrocyte-conditioned medium
(ACM) collected from immature hiPSC-Astros (hiPSC-Astro
ACM), hBrain-Astros (hBrain-Astro ACM), or mature hiPSC-
Astro (mature hiPSC-Astro ACM). We then examined the popu-
lation of oligodendroglial lineage cells in the culture at DIV 14
(Figure 2A). At DIV 7, there were bIIITubulin (bIIIT)+ neurons,
GFAP+ astrocytes, and OPCs labeled by NG2+; platelet-derived
growth factor receptor a (PDGFRa); or Olig2 but no myelin basic
protein (MBP)+ mature oligodendrocytes (Figure 2B). At DIV 14,
Figure 1. Differentiation of hiPSC-Astros to
Human Astrocytes with Mature Phenotypes
(A) Representative images of GFAP+ and S100b+
hiPSC-Astros and hBrain-Astros.
(B–D) Representative images of OTX2- (B),
HOXB4- (C), and NKX2.1-expressing cells (D) in
S100b+ hiPSC-Astros and hBrain-Astros.
(E) Representative images showing that expres-
sion of NF1A is abundant in immature hiPSC-
Astros but markedly reduced in mature hiPSC-
Astros and hBrain-Astros. Insets: enlarged images
from the square areas.
(F) Representative images of hCD44- and vi-
mentin-expressing cells in hiPSC-Astros, hBrain-
Astros, and mature hiPSC-Astros.
(G) The percentage of GFAP-, S100b-, OTX2-,
HOXB4-, and NKX2.1-expressing cells in hiPSC-
Astros and hBrain-Astros (n = 4 for each cell line).
All quantitative data for hiPSC-Astros are analyses
of pooled data collected from hiPSC1-Astros and
hiPSC2-Astros.
(H) qPCR analysis of NF1A, hCD44, and vimentin
(Vim) mRNA expression in the three groups of
human astrocytes (n = 4 from each cell line). One-
way ANOVA test, *p < 0.05, **p < 0.01, ***p < 0.001.
(I) qPCR analysis of EAAT1 and 2 mRNA expres-
sion in the three groups of human astrocytes (n = 4
from each cell line). One-way ANOVA test,
*p < 0.05.
(J) Glutamate uptake analysis showing that mature
hiPSC-Astros and hBrain-Astros exhibit glutamate
uptake at a higher rate than immature hiPSC-
Astros (n = 4 from each cell line). This uptake
capability is Na+-dependent and can be abolished
by Na+-free solution. One-way ANOVA test,
*p < 0.05.
(K) Proliferation rate of the three groups of human
astrocytes relative to HEK293 cells (n = 4 from
each cell line). One-way ANOVA test, *p < 0.05,
***p < 0.001.
Scale bars, 50 mm. Blue, DAPI-stained nuclei.oligodendroglial lineage cells identified by Olig2 staining were
found in the control group (Figures 2C and 2E), but few of them
were proliferating as indicated by not expressing Ki67 (Figures
2C and 2E). Compared with the control group, more Olig2+ cells
and Olig2+/Ki67+ proliferating cells were identified in the group
treated with mature hiPSC-Astro ACM and in the group treated
with hBrain-Astro ACM (Figures 2C and 2E). Notably, compared
with the mature hiPSC-Astro ACM and hBrain-Astro ACM
groups, the group treated with hiPSC-Astro ACM had many
more Olig2+ cells and Olig2+/Ki67+ proliferating cells (Figures
2C and 2E). For all groups, the vast majority (>93.0%) of Olig2+
cells were labeled by PDGFRa, indicating the nature of OPCs
(Figures 2D and 2F). Hence, human astrocytes promote the pro-
liferation of endogenous OPCs in primary culture. Immature
hiPSC-Astros have a much stronger capacity to promote OPC
proliferation than mature hiPSC-Astros and hBrain-Astros.Immature hiPSC-Astros Boost the Differentiation of
OPCs to Oligodendrocytes
We next examined the population of MBP+ mature oligodendro-
cytes 14 days (DIV 21) after addition of ACM (Figure 3A).We used
Olig1 to label the oligodendroglial cells in the cultures because
Olig2 expression might downregulate as the OPCs initiate the
myelination program (Jiang et al., 2013a). We found that, in the
control group, there were few MBP+ cells (Figures 3B and 3D),
and the majority of Olig1+ oligodendroglia expressed PDGFRa
(Figure 3C), indicating that OPCs in the control culture did not
robustly differentiate to oligodendrocytes and were stuck in the
progenitor cell stage. Compared with the control group, there
were more MBP+ cells in the mature hiPSC-Astro ACM and
hBrain-Astro ACM groups. Strikingly, large numbers of MBP+
oligodendrocytes were found in the hiPSC-Astro ACM group,
suggesting that hiPSC-Astro ACM promoted the differentiationCell Reports 15, 1303–1315, May 10, 2016 1305
Figure 2. The Effects of Immature and
Mature Human Astrocytes on OPC Prolifer-
ation
(A) A schematic showing that the primary mixed
neuron/glia culture at DIV 7 was treated with ACM
and that the proliferation of OPCs was examined
7 days after treatment with ACM (DIV 14).
(B) Representative images of bIIIT+ neurons,
GFAP+ astrocytes, and OPCs labeled by PDGFRa,
NG2, and Olig2 in mixed culture on DIV 7. There is
no MBP+ oligodendrocyte in the culture.
(C) Representative images of Olig2+ oligoden-
droglial lineage cells and Ki67+ proliferating cells
in the Cont culture and cultures fed with hiPSC-
Astro ACM,mature hiPSC-Astro ACM, and hBrain-
Astro ACM.
(D) Representative images of Olig2+ and PDGFRa+
in cultures fed with the different ACMs.
(E) The percentage of Olig2+ and Ki67+/Olig2+ cells
in cultures fed with the different ACMs (n = 3 from
each cell line). All quantitative data for hiPSC-
Astros and mature hiPSC-Astros are analyses of
pooled data collected from hiPSC1-Astros and
hiPSC2-Astros, and mature hiPSC1-Astros and
hiPSC2-Astros, respectively. One-way ANOVA
test; *p < 0.05, **p < 0.01, ***p < 0.001, comparison
between control group versus the groups treated
with the different ACMs; ##p < 0.01. NS, not sig-
nificant.
(F) Quantification of the percentage of PDGFRa+
cells over total Olig2+ cells (n = 3 from each cell
line). One-way ANOVA test, p > 0.05.
Scale bars, 50 mm.of OPCs to oligodendrocytes. Our previous study (Jiang et al.,
2013b) reported the generation of two subtypes of human astro-
cytes from hESCs, neural progenitor cells (NPC)-Astros and
Olig2PC-Astros. We observed that ACM collected from both of
these two subtypes of hESC-derived immature astrocytes also
strongly promoted OPC differentiation at DIV 21 (Figure S2), indi-
cating that the effects on OPC differentiation were common to all
immature astrocytes derived from hiPSCs and hESCs.
To examine the population of OPCs in the culture at DIV 21, we
double-stained Olig1 with PDGFRa. As expected, we found that
there were significantly more Olig1+ oligodendroglia in the
hiPSC-Astro ACM group (Figures 3C and 3D) compared with
the control group, mature hiPSC-Astro ACM group, and
hBrain-Astro ACM group. Moreover, significantly more Olig1+/
PDGFRa+ OPCs were found in the hiPSC-Astro ACM group (Fig-
ures 3C and 3D) than in the control group, mature hiPSC-Astro
ACM group, and hBrain-Astro ACM group. To further confirm
these findings, we performed qPCR to examine the gene expres-
sion ofOlig1; the mature oligodendroglial markersMbp, Plp, and1306 Cell Reports 15, 1303–1315, May 10, 2016Cnp; and the OPC marker Pdgfra. We
consistently observed that the hiPSC-
Astro ACM group had the highest
expression of Olig1 (Figure 3E). Gene
transcripts encoding mature oligoden-
drocyte markers were also highly ex-
pressed in the hiPSC-Astro ACM group.In particular, Mbp expression was 16.6-fold higher in the
hiPSC-Astro ACM group than in the control group. The expres-
sion of Plp and Cnp was, respectively, 9.2- and 2.1-fold higher
in the hiPSC-Astro ACM group in the control group. The expres-
sion of Pdgfra was lower (0.5-fold) in the mature hiPSC-Astro
ACM and hBrain-Astro ACM groups compared with the control
and hiPSC-Astro ACM groups. Together, these data indicate
that, compared with the addition of mature hiPSC-Astro ACM
or hBrain-Astros ACM, the addition of hiPSC-Astro ACM not
only replenishes the OPCs pool by robustly promoting OPC pro-
liferation but also strongly boosts the differentiation of OPCs to
oligodendrocytes.
Immature hiPSC-Astros Regulate OPC Differentiation
Partly via Release of TIMP-1
To explore the possible mechanisms underlying the effects of
immature hiPSC-Astros on OPCs, we added hiPSC-Astro ACM
to a purified culture of primary mouse OPCs and found that
hiPSC-Astro ACM similarly promoted the proliferation and
Figure 3. The Effects of Immature and
Mature Human Astrocytes on OPC Differen-
tiation
(A) A schematic showing that the differentiation of
OPCs to oligodendrocytes in the primary mixed
neuron/glia culture was examined after 14-day
treatment with ACM (DIV 21).
(B) Representative images of MBP+ oligodendro-
cytes and MAP2+ neurons in Cont culture and
cultures fed with hiPSC-Astro ACM, mature
hiPSC-Astro ACM, and hBrain-Astro ACM. The
squared areas are enlarged.
(C) Representative images of Olig1+ oligoden-
droglial lineage cells and PDGFRa+ OPCs in mixed
cultures fed with the different ACMs.
(D) Quantification of pooled data showing the
percentage of MBP+, Olig1+, and Olig1+/
PDGFRa+ cells in cultures fed with the different
ACMs (n = 3 from each cell line). One-way ANOVA
test; *p < 0.05, ***p < 0.001, comparison between
control group versus groups treated with the
different ACMs; ###p < 0.001.
(E) qPCR analysis of Olig1, Mbp, Plp, Cnp, and
Pdgfra expression in cultures fed with the different
ACMs (n = 3 from each cell line). One-way ANOVA
test; **p < 0.01, ***p < 0.001, comparison between
control group versus groups treated with the
different ACMs; ##p < 0.01, ###p < 0.001.
Scale bars, 50 mm. Blue, DAPI-stained nuclei.differentiation of OPCs in the purified culture (Figure S3), sug-
gesting that hiPSC-Astro ACM had direct effects on OPCs.
Then we performed a global gene expression microarray and
analyzed the data obtained from hiPSC1-Astros, hiPSC2-Astros,
and hESC-derived astrocytes, including NPC-Astros and
Olig2PC-Astros (GEO: GSE47515) (Chen et al., 2014a; Jiang
et al., 2013b). We focused on analyzing the genes encoding
astrocyte-secreted factors that were reported to directly regu-
late OPC proliferation and differentiation. The detailed informa-
tion of these genes is shown in Table S1. Notably, immature
astrocytes expressed gene transcripts encoding factors that
both promote myelination, such as TIMP-1, laminin and
thrombospondins (TSPs) (Figure 4A), and inhibit myelination,Cell Rsuch as connective tissue growth factor
(CTGF), tenascin C (TnC), and CXCL1
(Figure 4B). Moreover, immature astro-
cytes expressed gene transcripts encod-
ing PDGF and FGF2 (Figure 4C), which
are OPC mitogens. Therefore, the gene
expression of secreted factors with
various effects on OPCs may collectively
account for the composite effects of
immature astrocytes on OPCs.
Among the gene transcripts encoding
factors that promote myelination, we
found that the top highly expressed
gene was TIMP-1, which has been previ-
ously reported to critically regulate oligo-
dendrocyte development in mice (Moore
et al., 2011). We then verified the expres-sion of TIMP-1 in all human astrocytes by qPCR. The result
showed that TIMP-1 expression was abundant in immature
hiPSC-Astros and hESC-Astros (Figure 4D), whereas its expres-
sion was significantly decreased in mature hiPSC-Astros,
mature hESC-Astros, and hBrain-Astros (Figure 4D). To further
investigate the role of TIMP-1 in the effects of immature
hiPSC-Astros on OPC differentiation, we inhibited TIMP-1
expression in hiPSC-Astros by small interfering RNA (siRNA).
qPCR analysis showed that, 48 hr after transfection of TIMP-1
siRNA, TIMP-1 expression was significantly reduced (5.8-fold),
compared with hiPSC-Astros transfected with control siRNA
(Figure 4E). Next, we fed the primary mixed neuron/glia culture
at DIV 7 with conditioned medium collected from hiPSC-Astroseports 15, 1303–1315, May 10, 2016 1307
Figure 4. The Role of TIMP-1 in the Effects
of hiPSC-Astros on OPC Differentiation
(A–C) Gene expression analysis of immature
hiPSC-Astros (hiPSC1-Astro and hiPSC2-Astro)
and hESC-Astros (NPC-Astros and Olig2PC-
Astros). Shown are heatmaps focusing on gene
transcripts encoding factors that are secreted by
astrocytes and involved in promoting OPC differ-
entiation (A), inhibiting OPC differentiation (B), and
increasing OPC proliferation (C). High expression
relative to mean is colored red. Low expression is
colored green.
(D) qPCR analysis of TIMP-1 expression in imma-
ture hiPSC-Astros and hESC-Astros and in mature
hiPSC-Astros, hESC-Astros, and hBrain-Astros
(n = 4 for each cell line). One-way ANOVA test,
**p < 0.01.
(E) qPCR analysis of pooled data showing the
expression of TIMP-1 in hiPSC-Astros 48 hr after
transfection with Cont and TIMP-1 siRNA (n = 3–5
from each line). Student’s t test, **p < 0.01.
(F) Representative images of MBP+ oligodendro-
cytes and MAP2+ neurons in primary mixed
neuron/glia cultures fed with ContsiRNA ACM,
TIMP-1siRNA ACM, or TIMP-1siRNA ACM sup-
plemented with TIMP-1. The squared areas are
enlarged.
(G) Representative images of Olig1+ and PDGFRa+
cells in mixed cultures fed with the different ACMs.
(H) Quantification of pooled data showing the
percentage of MBP+, Olig1+, and Olig1+/
PDGFRa+ cells in cultures fed with the different
ACMs (n = 3 from each line). One-way ANOVA test,
*p < 0.05.
(I) qPCR analysis of pooled data showing Olig1,
Mbp, Plp, Cnp, and Pdgfra expression in cultures
fed with the different ACMs (n = 3 from each line).
One-way ANOVA test; *p < 0.05, **p < 0.01.
Scale bars, 50 mm. Blue, DAPI-stained nuclei.transfected with TIMP-1 siRNA (TIMP-1siRNA ACM), control
conditioned medium collected from hiPSC-Astros transfected
with control siRNA (ContsiRNA ACM), and TIMP-1siRNA ACM
supplemented with TIMP-1 (10 ng/ml). Then we examined OPC
differentiation at DIV 21. There were less MBP+ oligodendro-
cytes in the TIMP-1siRNA ACM group than in the ContsiRNA
ACMgroup (Figures 4F and 4H). Adding TIMP-1 to TIMP-1siRNA
ACM increased the percentage of MBP+ oligodendrocytes. The
total number of Olig1+ cells was not significantly different among
groups (Figures 4G and 4H), suggesting that TIMP-1 knockdown
did not change the effects on increasing OPC proliferation. We
also observed that there were more Olig1+/PDGFRa+ OPCs in
the TIMP-1siRNA ACM group compared with the ContsiRNA1308 Cell Reports 15, 1303–1315, May 10, 2016and TIMP-1siRNA plus TIMP-1 ACM
groups (Figures 4G and 4H). Our qCPR
results further confirmed these observa-
tions. Olig1 expression was not signifi-
cantly different among the three groups
(Figure 4I). The TIMP-1siRNA ACM group
had significantly lower expression of
the mature oligodendrocyte genes Mbp(0.5-fold), Plp (0.5-fold), and Cnp (0.6-fold) compared with
the ContsiRNA and TIMP-1siRNA plus TIMP-1 ACM groups.
Together, these data indicate that TIMP-1 secreted by immature
hiPSC-Astros contributes to their effects on promoting OPC
differentiation but not to their effects on increasing OPC
proliferation.
Transplanted Immature hiPSC-Astros Promote
Myelination in a Mouse Model of PVL
Considering the effects of immature hiPSC-Astros on OPCs
in vitro, we hypothesized that transplantation of immature
hiPSC-Astros might promote myelination after PVL injury. To
facilitate the survival of transplanted cells, we induced insults
Figure 5. Transplantation of Immature
hiPSC-Astros into Rag1/ Mouse Brains
Subjected to PVL
(A) A schematic showing the timeline for the in vivo
experiments from P6–P60.
(B) Left: a cresyl violet-stained coronal brain sec-
tion at the level of the hippocampus, where ana-
lyses occurred. The red box outlines the white
matter area used for immunohistochemical ana-
lyses of the PVL insult. Right: a diagram showing
the cell transplantation site, which is adjacent to
the injured white matter area.
(C) Representative images showing that grafted
hiPSC-Astros are identified by hN staining on P11.
The transplanted hiPSC-Astros are also identified
by hCD44 but negative for MBP staining. The
squared areas in the center are enlarged at the
bottom. Arrowheads indicate hN+/GFAP+ cells.
LV, lateral ventricle; HIP, hippocampus.
(D) Top: representative images showing that there
are more Olig2+ oligodendroglial cells on the Ipsi
side than on the Contra side of the brain in both the
vehicle and hiPSC-Astro groups. Transplantation
of hiPSC-Astros further increases the expansion of
Olig2+ cells on the Ipsi side. Bottom: representa-
tive images showing that, in the vehicle group,
MBP expression in the CC is only decreased
substantially on the Ipsi side, with no significant
changes on the Contra side. Transplantation of
hiPSC-Astros promotes myelination on the Ipsi
side and has no significant effect on the uninjured
Contra side.
(E) The number of Olig2+ cells in the analyzed area
(n = 4 for each group). Student’s t test; **p < 0.01,
***p < 0.001, comparison between the Ipsi side
versus the Contra side; ##p < 0.01.
(F) Fluorescence intensity (FI) of MBP staining
(n = 4 for each group). Data represent the FI value
normalized to the Contra side brains of the vehicle
group. Student’s t test; *p < 0.05, ***p < 0.001,
comparison between Ipsi side versus Contra side;
#p < 0.05.
(G) Representative images and quantification of
Olig2+/CC1+ and Olig2+/CC1 cells in the Ipsi-side
brains of the vehicle and hiPSC-Astro groups.
Arrows indicate Olig2+/CC1+ cells, and arrow-
heads indicate Olig2+/CC1cells. Student’s t test;
**p < 0.01, ***p < 0.001; n = 4 for each group.
(H) Representative images and quantification
showing that the majority of hN+ transplanted
hiPSC-Astros are positive for human TIMP-1
(hTIMP-1) staining on P11 (n = 4).
Scale bars, 50 mm. Blue, DAPI-stained nuclei.in P6Rag1/ immunodeficient mice using unilateral carotid liga-
tion followed by hypoxia, which resulted in selective injury to the
subcortical white matter without detectable injury to cortical
neurons (Liu et al., 2011a; Shen et al., 2010). Consistent with
our previous studies (Liu et al., 2011a; Shen et al., 2010), we
observed reactive astrogliosis 4 days after induction of PVL
injury selectively in the ipsilateral (Ipsi) side of the brain (Figures
S4A–S4C). The contralateral (Contra) side of the brain was not
significantly changed after PVL injury and was used as a control.
Because of the extremely low proliferation rate of mature hiPSC-
Astros and hBrain-Astros (Figure 1K) and the low engraftmentefficiency commonly seen from transplantation of terminally
differentiated mature cells, it was technically difficult to collect
ample mature human astrocytes and perform transplantation
experiments with a good cell survival rate. Thus, we only trans-
planted immature hiPSC-Astros into the mouse brain on post-
natal day 7 (P7) when we started to see reactive astrocytes
(Figure 5A). Immature hiPSC-Astros were grafted to the periven-
tricular area adjacent to the corpus callosum (CC), where hypo-
myelination was observed (Liu et al., 2011a; Shen et al., 2010)
(Figure 5B). No tumor formation or overgrowth of transplanted
cells was observed throughout the experiments. TransplantedCell Reports 15, 1303–1315, May 10, 2016 1309
hiPSC-Astros identified by human nuclei (hN) staining survived in
themouse brains at 4 days after transplantation (P11) (Figure 5C).
Themajority of the transplanted cells were found located close to
the hippocampus and the lateral ventricle. Similar to our previous
transplantation studies (Jiang et al., 2013b), a small percentage
of the hiPSC-Astros expressed GFAP in vivo 4 days after trans-
plantation, as indicated by the double-labeling of GFAP and hN
(Figure 5C; 9.2% ± 1.4% of the hN+ cells were GFAP+, n = 4). The
transplanted cells did not differentiate to oligodendrocytes, as
indicated by expression of hCD44 but lack of MBP and Olig2
(Figure 5C; Figure S4D). Next we examined the number of oligo-
dendroglial lineage cells in the CC. Consistent with previous
studies (Jablonska et al., 2012; Reid et al., 2012; Segovia
et al., 2008), in the vehicle control group, the number of Olig2+
oligodendroglia was increased on the ipsilateral side compared
with the contralateral side (Figures 5D and 5E). Transplantation
of hiPSC-Astros further increased the number of Olig2+ cells in
the CC of the ipsilateral side but did not significantly affect the
contralateral side (Figures 5D and 5E). Similar to our previous
studies (Liu et al., 2011a), we observed severe hypo-myelination
selectively on the ipsilateral side 4 days after PVL insult, as indi-
cated by MBP staining (Figures 5D and 5F). Quantification of the
fluorescence intensity of MBP staining revealed that there was
higher MBP immuno-positivity on the ipsilateral side in the
hiPSC-Astro group than in the vehicle control group (Figures
5D and 5F). We further examined the number of immature and
mature oligodendroglia, respectively, identified by Olig2+/CC1
and Olig2+/CC1+ on the ipsilateral sides of the vehicle and
hiPSC-Astro groups. There were significantly more immature
and mature oligodendroglia cells in the hiPSC-Astro group
than in the vehicle group (Figure 5G). To further confirm that
transplanted immature hiPSC-Astros promoted myelination,
we examined the node of Ranvier and the density of myelinated
axons on the ipsilateral side of brains of the vehicle and hiPSC-
Astro groups. Consistently, there were more nodes of Ranvier,
identified by b IV spectrin+ staining flanked by Caspr+ staining,
in the hiPSC-Astro group compared with the vehicle group (Fig-
ure S4E). Moreover, the electron microscopic analyses demon-
strated that the density of myelinated axons in the hiPSC-Astro
group was significantly higher than that in the vehicle group (Fig-
ure S4F). In addition, the majority of transplanted hiPSC-Astros
abundantly expressed TIMP-1 at this time point (Figure 5H).
We also transplanted immature TIMP-1siRNA hiPSC-Astros in
which TIMP-1 expression was inhibited. MBP immuno-positivity
on the ipsilateral sides on P11 in the TIMP-1siRNA hiPSC-Astro
and vehicle control groups was not significantly different (Fig-
ure S4G), suggesting that TIMP-1 secreted by transplanted
hiPSC-Astros crucially contributes to the maturation of endoge-
nous OPCs.
Transplanted Immature hiPSC-Astros Promote the
Recovery of Behavioral Performance and Myelination
To examine the behavioral performance of the animals, three
groups of animals were used: a sham group, in which animals
received sham PVL surgery and no vehicle PBS injection or
cell transplantation; a vehicle group, in which animals received
PVL surgery and a PBS injection after the surgery; and a
hiPSC-Astro group, in which animals received PVL surgery and1310 Cell Reports 15, 1303–1315, May 10, 2016hiPSC-Astro transplantation after the surgery. Consistent with
our previous study, we observed no significant difference in
motor function when climbing on the wall with a slope angle of
45 (Liu et al., 2011a) from P11 to P21 among the three groups
of animals. Myelin mass changes are highly associated with
the higher functions of the brain (Liu et al., 2012). Accumulative
studies have shown that myelination deficiency contributes to
the development of long-term deficits in learning and memory
in both mouse and rat models of PVL (Cengiz et al., 2011; Huang
et al., 2009). We thus examined the learning and memory ability
of P60 adult mice in a Morris water maze. All mice were able to
swim normally and locate the hidden platform during training tri-
als in the Morris water maze test. As expected, mice in the
vehicle group showed worse performance and required more
time to find the platform than those in the sham group. Analysis
of the escape latency revealed significant differences among
the sham, vehicle, and hiPSC-Astro groups (Figures 6A and
6C, (1)–(3)). On navigation days 3–5, mice in the sham group
showed less escape latency compared with mice in the vehicle
group. Notably, on navigation days 4 and 5, mice in hiPSC-Astro
group showed better performance compared with mice in the
vehicle group. In the probe trials, mice in the sham and hiPSC-
Astro groups showed better performance and spent significantly
more time than mice in the vehicle group in the quadrant where
the platform had been (Figures 6B and 6C, (4)–(6)). Moreover, we
examined the distribution of transplanted hiPSC-Astros in P60
animals. hN+ cells were found close to the lateral ventricle and
integrated into the hippocampus close to the CA3 region (Fig-
ure S5A). These transplanted cells maintained their astroglial
lineage properties, as indicated by over half of them expressing
GFAP (58.7% ± 3.4%, n = 7). However, at this time point, expres-
sion of TIMP-1 was undetectable in these transplanted hiPSC-
Astros (Figure S5B). We did not observe any abnormal cellular
hypertrophy and massive proliferation of the vast majority of
transplanted hiPSC-Astros, indicating that the transplanted
hiPSC-Astro did not become reactive astrocytes.
Next, to further explore the differences in myelination that
might contribute to the changes in behavioral performance, we
first examined MBP expression in the vehicle and hiPSC-Astro
groups on P60.We found that there was no significant difference
in MBP immuno-positivity between the contralateral and ipsilat-
eral sides in the vehicle and hiPSC-Astro groups (Figures S5C
and S5D). Previous studies have demonstrated that cellular re-
covery in oligodendrocytes does not correlate with proper
axonal myelination (Jablonska et al., 2012). We thus used elec-
tron microscopy to determine whether, in our model, neonatal
hypoxic-ischemic injury caused abnormalities in the ultrastruc-
ture of myelinated axons on P60. We found that unmyelinated
axons were distributed among myelinated axons in the vehicle
group (Figures 6D and 6E). Compared with the sham group,
the density of myelinated axons in the vehicle group was signif-
icantly lower (Figure 6F). The density of myelinated axons in the
hiPSC-Astro groupwas similar to that in the shamgroup andwas
significantly higher than that in the vehicle group (Figure 6F).
Under higher magnification, some myelinated axons exhibited
a thinner myelin sheath in the vehicle group compared with the
sham and hiPSC-Astro groups (Figure 6G). A scatterplot graph
of the g ratio analysis in Figure 6H demonstrated that the g ratio
Figure 6. The Effects of Transplanted
Immature hiPSC-Astros on Behavioral Re-
covery and Myelin Ultrastructure
(A) A Morris water maze task was performed on
P60 to test the spatial learning ability of sham-
(n = 7), vehicle- (n = 8), and hiPSC-Astro-trans-
planted (n = 10) groups, as shown by the time
(escape latency) to find the submerged platform
on navigation days 1–5. Two-way ANOVA test;
*p < 0.05, comparison between the vehicle group
and the sham group; #p < 0.05, comparison be-
tween the vehicle group and the hiPSC-Astro
group.
(B) Probe trials were performed 4 hr after the last
maze trails on navigation day 5, monitored by
relative radial quadrant occupancy (time spent in
the target radial quadrant) (n = 7–10). One way
ANOVA test; *p < 0.05, comparison between the
vehicle group and the sham group; #p < 0.05,
comparison between the vehicle group and the
hiPSC-Astro group.
(C) Representative sample paths from the maze
trials ((1)–(3)) and the search patterns in the probe
trials ((4)–(6)). (1) and (4), sham group; (2) and (5),
vehicle group; (3) and (6), hiPSC-Astro group.
(D) Low-magnification electron micrographs
showing a portion of the corpus callosum from the
animals in the sham, vehicle, and hiPSC-Astro
groups.
(E) An enlarged image from the vehicle group
showing axons that have no compact myelin
sheath (nma) among axons with myelin (ma).
(F) The density of myelinated axons of each group
(n = 3 mice/group). One-way ANOVA test; *p <
0.05, comparison between the vehicle group and
the sham group; #p < 0.05 comparison between
the vehicle group and the hiPSC-Astro group.
(G) Representative electron micrographs in high
magnification. Line A indicates the diameter of a
myelinated axon fiber, and line a indicates the
diameter of the axonal caliber.
(H) A scatterplot showing the relationship between
the g ratio values and axon diameters in the three
groups (n = 3 mice/group).
(I) Mean g ratio of the three groups (n = 3 mice/
group). One-way ANOVA test; **p < 0.01, com-
parison between the vehicle group and the sham
group; ##p < 0.01, comparison between the
vehicle group and the hiPSC-Astro group.values from the vehicle group were mostly between 0.8–0.9.
However, the g ratio values from the sham and hiPSC-Astro
groups largely overlapped and were mostly between 0.7–0.8,
with some being around 0.6. Notably, the majority of low-caliber
axons were unmyelinated in the vehicle group (Figure 6D), and,
thus, manymyelinated axons with large diameters were included
in the g ratio analysis (Figure 6H). Compared with the vehicle
group, the sham and hiPSC-Astro groups had significantly lower
g ratio values (Figure 6I). The effects of transplanted hiPSC-
Astros on both the density of myelinated axons and the g ratio
may indicate their effect on axons in addition to their effect on
oligodendroglia myelination. Moreover, the significant but small
differences in the density of myelinated axons among the groups
may suggest that, under all conditions, oligodendrocytes areable to mature into myelin-forming cells, but the maturation is
accelerated in the sham and hiPSC-Astro groups compared
with the vehicle group.
Intranasal Administration of Immature hiPSC-Astro
ACM Promotes OPC Maturation After PVL Injury
To further compare the effects of immature and mature human
astrocytes on OPCmaturation after PVL injury and to investigate
the role of TIMP-1, we intranasally applied the total concentrated
factors collected from ACM. Similar to the mouse PVL model,
unilateral carotid ligation followed by hypoxia (6% O2 for 1 hr)
in rats on P7 also resulted in selective white matter injury without
evident injury to cortical neurons (Follett et al., 2000). Here we
used the rat model of PVL to facilitate intranasal administrationCell Reports 15, 1303–1315, May 10, 2016 1311
Figure 7. Intranasal Administration of ACM
in a Rat Model of PVL
(A) A schematic showing the timeline for intranasal
administration of ACM from P8–P11.
(B) Representative images of Olig2+ oligoden-
droglial cells and Olig2+/Ki67+ proliferating oligo-
dendroglial cells, in Ipsi- and Contra-side brains
from rats that received intranasal administration of
Cont medium, ContsiRNA ACM, TIMP-1siRNA
ACM, and mature hiPSC-Astro ACM. Arrowheads
indicate Olig2+/Ki67+ cells.
(C) Representative images of MBP expression in
the CC of both Contra- and Ipsi-side brains from
the four groups.
(D) Representative images of Olig2+ and NG2+
cells in the CC of the Ipsi-side brains from the
ContsiRNA ACM and TIMP-1siRNA ACM groups.
Arrowheads indicate Olig2+/NG2+ cells.
(E and F) The number of Olig2+ cells (E) and Olig2+/
Ki67+ cells (F) in the analyzed area (n = 4 for each
group). Student’s t test; *p < 0.05, ***p < 0.01,
comparison between the Ipsi side and the
Contra side within the different groups; ##p < 0.01,
###p < 0.001, comparison between the Ipsi or
Contra side from the Cont medium group and
those from the other groups.
(G) FI of MBP staining (n = 4 for each group). Data
represent the FI value normalized to the Contra-
side brain of the Cont medium group. Student’s
t test; *p < 0.05, ***p < 0.001, comparison between
the Ipsi side and the Contra side within the
different groups; ##p < 0.01, comparison between
the Ipsi or Contra side from the Cont medium
group versus those from the other groups.
(H) The number of Olig2+/NG2+ cells in the CC of
the Ipsi-side brains from the ContsiRNA ACM and
TIMP-1siRNA ACM groups (n = 4 for each group).
Student’s t test, **p < 0.01.
Scar bars, 50 mm.because neonatal rats have more easily visible nares than
neonatal mice. Starting on P8, we applied control (Cont) medium
that had not been exposed to cells, concentrated mature hiPSC-
Astro ACM, as well as ContsiRNA ACM and TIMP-1siRNA
ACM, collected from immature hiPSC-Astros transfected with
control and TIMP-1 siRNA, respectively (Figure 7A). The ELISA
confirmed the higher abundance of human TIMP-1 in ContsiRNA
ACM than that in TIMP-1siRNA ACM or mature hiPSC-Astro
ACM (Figure S6A). The intranasal route allowed effective delivery
directly to the brain from the nasal mucosa, as indicated by
ELISA of the brain tissues collected 1 hr after the last intranasal
administration (Figure S6B). On P11, we found that administra-1312 Cell Reports 15, 1303–1315, May 10, 2016tion of both ContsiRNA and TIMP-1siRNA
ACM significantly increased the number
of Olig2+ oligodendroglia not only on the
ipsilateral side but also on the contralat-
eral side of the brain compared with
administration of Cont medium and
mature hiPSC-Astro ACM (Figures 7B
and 7E). There were also more prolifer-
ating oligodendroglial cells, identified byKi67+ and Olig2+, on both the ipsilateral and contralateral sides
in the ContsiRNA and TIMP-1siRNA ACM groups than in the
Cont medium and mature iPSC-Astro ACM groups (Figures 7B
and 7F). MBP staining revealed that there was higher MBP
immuno-positivity in ipsilateral side brain from the ContsiRNA
ACM group than in the Cont medium group (Figures 7C and
7G), indicating that ACM from immature hiPSC-Astros promoted
OPCmaturation. Administration of TIMP-1siRNA ACM ormature
hiPSC-Astro ACMwas not able to promote OPCmaturation after
PVL injury (Figures 7C and 7G). Because there was an increased
number of Olig2+ cells but no MBP immuno-positivity in the ipsi-
lateral side from the TIMP-1siRNA ACM group, we further
investigated whether these cells stayed at a progenitor stage. In
the CC of the ipsilateral side, more Olig2+ cells expressing the
OPC marker NG2 were found in the TIMP-1siRNA ACM group
than in the ContsiRNA ACM group (Figures 7D and 7H).
Together, these results demonstrate that released factors such
as TIMP-1mediate the effects of immature hiPSC-Astros on pro-
moting OPC maturation after PVL injury.
DISCUSSION
By differentiating hPSCs to astrocytes with defined immature
and mature phenotypes, we report a novel regulation of oligo-
dendrocyte development by astrocytes at a previously under-
studied immature stage. We demonstrate that hiPSC-derived
immature astroglial transplantation or ACM promotes myelino-
genesis and improves the behavioral outcome in animal models
of PVL. These results implicate a novel strategy for promoting
myelinogenesis by hiPSC-derived immature astroglia.
Because of a lack of efficient methods for purifying and main-
taining astrocytes with defined immature and mature pheno-
types in culture (Foo et al., 2011), no specific studies have
been performed to examine how astrocytes at specific
developmental stages interact with oligodendrocytes. Krencik
et al. (2011) showed that hPSC-Astros become mature under
serum-free conditions after a long period of time (180 days). Roy-
bon et al. (2013) reported that hPSC-Astros cultured in a serum-
containing medium (1% fetal bovine serum) exhibit mature
phenotypes after a short exposure to FGF1 (7 days). Here we
promote thematuration of hiPSC-Astros in a serum-freemedium
containing FGF1. We find that, after 30- to 50-day culture, imma-
ture hiPSC-Astros become mature, as indicated by increased
EAAT1 expression and glutamate uptake and decreased expres-
sion of NF1A, hCD44, and vimentin, consistent with observations
of astrocyte maturation in human tissue (Bjo¨rklund et al., 1984;
Girgrah et al., 1991; Yamada et al., 1992). Moreover, immature
and mature hiPSC-Astros also possess a forebrain identity
similar to hBrain-Astros. Thus, using our protocol, immature
and mature human astrocytes could be efficiently derived from
hPSCs, providing new opportunities to study human astrocyte
development and developmental interactions between astroglia
and oligodendroglia.
Our microarray gene analyses show that immature human
astrocytes express gene transcripts encoding OPC mitogens
and factors that inhibit OPC maturation to myelinating oligoden-
drocytes. We propose that the inhibitory factors and OPC
mitogens work synergistically to promote OPC proliferation.
Moreover, immature astrocytes express gene transcripts en-
coding factors that promote OPC maturation and myelination.
By a combination of qPCR, siRNA knockdown, and intranasal
ACM administration experiments, we provide both in vitro and
in vivo evidence that TIMP-1 partially but critically mediates
the effects of immature astrocytes on OPC differentiation but
not the effects on OPC proliferation. Hence, the effects of
hiPSC-Astros on oligodendroglia could depend on the stage
in which the oligodendroglia cells are and to which astrocyte-
secreted factors the oligodendroglia cells are exposed. The
gene expression of secreted factors with multifaceted effects
on OPCs may indicate fine regulatory effects of immature astro-cytes on oligodendroglial lineage progression. In addition, by
analyzing a transcriptome database of mouse astrocytes
(Cahoy et al., 2008), we consistently find that mouse immature
astrocytes also express gene transcripts encoding factors that
promote or inhibit myelination and promote OPC proliferation
(Figures S7A–S7D). Interestingly, Tgfb2, encoding transforming
growth factor b2 (TGF-b2), but not Timp-1, is prominently ex-
pressed in immature mouse astrocytes (Figures S7B and
S7E). Previous studies have demonstrated that the TGF-b
signaling pathway critically promotes oligodendrocyte differen-
tiation (Palazuelos et al., 2014). Thus, it would be interesting to
investigate whether immature human and mouse astrocytes
regulate oligodendrocyte development through different mech-
anisms. The iPSC technology provides new opportunities to
obtain human glial cells and to study their interactions. With
further advancement and development in purification and sep-
aration of human astroglia and oligodendroglia (Sim et al.,
2011), future studies are warranted to provide deep insights
into human glial cell interactions.
Our in vitro findings indicate that immature hiPSC-Astros not
only promote OPC proliferation but also robustly boost OPC dif-
ferentiation to oligodendrocytes. We further demonstrate that
forebrain immature hiPSC-derived astroglial transplants rescue
hypo-myelination in a hypoxic/ischemic mouse model of PVL.
We find that TIMP-1 expression is abundant in transplanted
hiPSC-Astros 4 days after transplantation and undetectable
about 2 months after transplantation, which is consistent with
our in vitro observation (Figure 4D) and previously reported
developmental regulation of TIMP-1 expression in astrocytes
(Ulrich et al., 2005). Furthermore, our study of intranasal admin-
istration of ContsiRNA and TIMP-1siRNA ACM pinpoints the role
of TIMP-1 inmediating the effects of ACMon promoting OPCdif-
ferentiation in vivo. Taken together, through released factors
such as TIMP-1, hiPSC-Astros promote myelination and behav-
ioral recovery.
Intracerebral cell transplantation during the neonatal period
is not ideal in clinical settings. We demonstrate that direct
application of hiPSC-Astro ACM via intranasal administration
promotes myelination after PVL injury. This study thus puts for-
ward the notion of hiPSC-based cell-free therapy. It is tempting
to suggest that this approach may be particularly useful in
myelin disorders such as multiple sclerosis, where an inflamed
environment significantly compromises the survival of trans-
planted cells. Administration of the cell-free, concentered fac-
tors that are released from human immature astrocytes may
be effective in promoting remyelination (Chen et al., 2014b).
Future secretomic studies may help identify more comprehen-
sively all key factors released from hiPSC-Astros and further




The two hiPSC lines hiPSC1 and hiPSC2 were reprogrammed from healthy
individuals’ fibroblasts by using retroviruses encoding OCT4, SOX2, KLF4,
and c-MYC (Figure S1A; Chen et al., 2014a). All experiments conducted on
hPSCs were approved by the Stem Cell Research Oversight Committee at
the University of California, Davis.Cell Reports 15, 1303–1315, May 10, 2016 1313
Differentiation and Culture of Human Astrocytes
An embryoid body-based differentiation procedure was used for astroglial dif-
ferentiation of hiPSCs (Figure S1B). The hBrain-Astros were isolated from the
cerebral cortex of fetal human brains (ScienCell, catalog no. 1800).
Generation of Astrocyte-Conditioned Medium
ACMwas concentrated 50-fold using centrifugal concentrators (Millipore). The
protein concentration was determined by BCA assay (Thermo Scientific), and
ACM was fed to a primary mixed neuron/glia culture at 100 mg/ml. TIMP-
1siRNA ACM supplemented with TIMP-1 (10 ng/ml, PeproTech) was also
fed to the primary culture.
Immunostaining
Cells fixed with 4% paraformaldehyde and brain sections (18 mm thick) from
P11–P60 mice and rats were processed for immunofluorescence staining
(Liu et al., 2011b). The information for primary antibodies and dilutions is listed
in Table S2. Images were captured using a Nikon Eclipse C1 or Nikon A1
confocal laser-scanning microscope.
Microarray Analysis and Heatmaps
An Illumina bead array was performed for gene expression analysis (Liu et al.,
2006). The array datawere processed usingGenomeStudio software (Illumina).
PVL Animal Model
Animal experiments were performed following protocols approved by the
Animal Care and Use Committees at the University of California, Davis. By uni-
lateral carotid ligation (UCL) followed by hypoxia, we induced hypoxic/
ischemic insults in P6 mouse pups of Rag1/ immunodeficient mice
(B6.129S7-Rag1tm1MomonaC57BL/6background, TheJacksonLaboratory)
or P7 Long-Evans rat pups (Charles Rivers Laboratories) (Follett et al., 2000).
Cell Transplantation
One day after induction of hypoxic/ischemic injury in mice (P7), cell transplan-
tation was performed (Figure 5A). A Hamilton syringe and needle were used to
deliver cells by insertion directly through the skull into the target site (Chen
et al., 2014a).
Intranasal Administration
One day after induction of hypoxic/ischemic injury in rats, intranasal adminis-
tration of concentrated ACM was performed (Figure 7A). Control medium or
ACM was administered every 12 hr from P8–P11.
Electron Microscopy
Brain tissues were fixed and sectioned as described previously (Jiang et al.,
2013a). Electron microscopy (EM) images were captured using a high-resolu-
tion charge-coupled device (CCD) camera (Gatan). Images were processed
using DigitalMicrograph (Gatan). EM images were analyzed using ImageJ
software.
Morris Water Maze Test
The Morris water maze test was performed with mice on P60 (Jiang et al.,
2013b).
Data Analysis
For all experiments, the analysis was derived from at least three independent
experiments. All data are represented as mean ± SEM. The escape latency in
the behavioral training tests was determined by two-way repeated measures
ANOVA. All other assessments were analyzed using Student’s t test when
only two groups were compared or one-way ANOVA when three or more
groups were compared.
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